Form D · Pharmaceuticals

Rib-X Pharmaceuticals, Inc.

New Haven, CT · CIK 0001164994

Offering snapshot reported Nov 30, 2012 · SEC filing

Reported sold
$18.7M
Offering amount: $67.5M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 15, 2012
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 30, 2012Initial$18,686,500No comparison4SEC filing
Jan 28, 2011Initial$5,500,000No comparison11SEC filing
Jun 10, 2010Initial$5,500,000No comparison16SEC filing
Oct 12, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Jun 26, 2006PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-187690

Source: Form D, filed Nov 30, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
C. Boyd Clarke Director
Robert Conerly Executive
Jonathan Fleming Director
Cecilia Gonzalo Director
Peter Greenleaf Director
Jonathan S. Leff Director
Mark Leuchtenberger Director, Executive
George Milne Director
George M. Milne, Jr. Director
Harry H. Penner, Jr. Director
Raymond Whitaker Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
300 George Street Suite 301
New Haven, CT, 06511